OTLK - OUTLOOK THERAPEUTICS INC

OTLK - OUTLOOK THERAPEUTICS INC

https://www.outlooktherapeutics.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight ( EIS )

GlobeNewswire • 1 week, 5 days ago • score: 0.45

ISELIN, N.J., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Outlook Therapeutics, Inc. ( Nasdaq: OTLK ) , a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight ...

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight ( EIS )

Business Insider • 1 week, 5 days ago • score: 0.45

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) ...

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight ( EIS ) - Outlook Therapeutics ( NASDAQ:OTLK )

Benzinga • 1 week, 5 days ago • score: 0.40

ISELIN, N.J., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Outlook Therapeutics, Inc.

Outlook Therapeutics Requests Type A Meeting with FDA

GlobeNewswire • 1 week, 6 days ago • score: 0.04

ISELIN, N.J., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Outlook Therapeutics, Inc. ( Nasdaq: OTLK ) , a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has been submitted to the ...

Outlook Therapeutics Requests Type A Meeting with FDA

Business Insider • 1 week, 6 days ago • score: 0.29

Outlook Therapeutics Requests Type A Meeting with ...

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Zacks Commentary • 2 weeks, 3 days ago • score: 0.20

Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.

FDA Rejects Outlook Therapeutics Eye Drug For Second Time - Outlook Therapeutics ( NASDAQ:OTLK )

Benzinga • 2 weeks, 4 days ago • score: 0.24

FDA rejects ONS-5010 BLA citing lack of efficacy evidence, despite positive NORSE TWO trial results. Stock trades on heavy volume at 26.41 million, far above its 1.51 million average daily volume. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day Outlook Therapeutics, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.

52W High

$8.32

52W Low

$0.79

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.49

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

2.85

EV/EBITDA (<8 favorable)

-4.13

EV/Revenue (<3 favorable)

44.73

P/S (TTM) (<3 favorable)

27.59

P/B (<3 favorable)

10.19

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

36.39%

Institutions (25–75% balanced)

20.54%

Shares Outstanding

44,419,500

Float

25,057,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,505,300

Gross Profit (TTM)

-40,371,696

EPS (TTM)

-0.84

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-10.46%

ROE (TTM) (>15% strong)

-0.04%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

6.58

Momentum

Bearish momentum

Value

-0.3875

Previous

-0.4024

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025